These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33020270)

  • 1. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
    Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
    Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
    Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
    Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
    DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites.
    Chen Y; Zhang H; Xu Z; Tang H; Geng A; Cai B; Su T; Shi J; Jiang C; Tian X; Seluanov A; Huang J; Wan X; Jiang Y; Gorbunova V; Mao Z
    Nucleic Acids Res; 2019 Sep; 47(16):8563-8580. PubMed ID: 31291457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
    Geng L; Zhu M; Luo D; Chen H; Li B; Lao Y; An H; Wu Y; Li Y; Xia A; Shi Y; Tong Z; Lu S; Xu D; Wang X; Zhang W; Sun B; Xu Z
    Oncogene; 2024 Feb; 43(9):682-692. PubMed ID: 38216672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
    Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
    Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
    Guan J; Zhao Q; Mao W
    Biochim Biophys Acta; 2016 Dec; 1863(12):3106-3115. PubMed ID: 27741411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
    Jiang Y; Yam JC; Chu WK
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
    Yang S; Wang XQ
    BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tanshinone I suppresses hepatocellular carcinoma cells growth through targeting DNA double-strand break repair.
    Qian Z; Feng N; Geng A
    Cancer Biol Ther; 2023 Dec; 24(1):2229958. PubMed ID: 37408176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czy┼╝ M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
    Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
    Bhattacharjee S; Nandi S
    IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC.
    Sun C; Jing W; Xiong G; Ma D; Lin Y; Lv X; Zhao Y; Ma X; Zhu L; Shen X; Yang M; Qin Z; Cheng Y; Xuan H; Li T; Han L
    Cancer Lett; 2022 Feb; 526():180-192. PubMed ID: 34762994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
    Reilly NM; Yard BD; Pittman DL
    Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.